← FDA DRUG APPROVALS

FDA ANDA · ANDA201157

LEVETIRACETAM

Sponsor: PHARM ASSOC

APPLICATION
ANDA201157
TYPE
ANDA
ORIGINAL APPROVAL
2015-06-04
LATEST ACTION
2024-11-13
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

LEVETIRACETAMPrescription
LEVETIRACETAM 100MG/ML · SOLUTION · ORAL

Approval history

2024-11-13Labeling · Supplement 12 · standardAP
2023-11-21Labeling · Supplement 11 · standardAP
2023-05-22Labeling · Supplement 8 · standardAP
2020-07-08Labeling · Supplement 6 · standardAP
2020-07-08Labeling · Supplement 4 · standardAP
2020-07-08Labeling · Supplement 5 · standardAP
2020-07-08Labeling · Supplement 1 · standardAP
2015-06-04Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →